SQZ Biotechnologies Company (SQZB)
OTCMKTS · Delayed Price · Currency is USD
0.0280
0.00 (0.00%)
May 13, 2025, 4:00 PM EDT

SQZB Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Period Ending
Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Revenue
21.4827.12120.1112.67
Revenue Growth (YoY)
-20.74%29.05%4.42%58.73%-
Cost of Revenue
70.9870.1551.5536.124.38
Gross Profit
-49.51-43.05-30.55-15.99-11.71
Selling, General & Admin
26.3225.7220.5118.278.69
Operating Expenses
26.3225.7220.5118.278.69
Operating Income
-75.83-68.77-51.06-34.27-20.4
Interest Expense
-----0.06
Interest & Investment Income
1.220.040.552.070.98
Other Non Operating Income (Expenses)
-0-0.01-0.01-0.010.24
EBT Excluding Unusual Items
-74.61-68.74-50.52-32.2-19.25
Merger & Restructuring Charges
-4.86----
Other Unusual Items
-----0.98
Pretax Income
-79.46-68.74-50.52-32.2-20.23
Net Income
-79.46-68.74-50.52-32.2-20.23
Net Income to Common
-79.46-68.74-50.52-32.2-20.23
Shares Outstanding (Basic)
2928522
Shares Outstanding (Diluted)
2928522
Shares Change (YoY)
4.47%410.54%216.92%13.12%-
EPS (Basic)
-2.76-2.49-9.35-18.89-13.43
EPS (Diluted)
-2.76-2.49-9.35-18.89-13.43
Free Cash Flow
-84.07-82.75-44.33-35.6619.79
Free Cash Flow Per Share
-2.92-3.00-8.21-20.9213.13
Gross Margin
-230.50%-158.87%-145.48%-79.53%-92.43%
Operating Margin
-353.04%-253.78%-243.16%-170.40%-161.06%
Profit Margin
-369.98%-253.68%-240.60%-160.14%-159.71%
Free Cash Flow Margin
-391.43%-305.37%-211.11%-177.33%156.22%
EBITDA
-74.32-67.56-49.72-32.88-19.34
EBITDA Margin
--249.32%-236.76%-163.51%-152.63%
D&A For EBITDA
1.51.211.341.381.07
EBIT
-75.83-68.77-51.06-34.27-20.4
EBIT Margin
--253.78%-243.16%-170.40%-161.05%
Revenue as Reported
21.4827.1-20.1112.67
Updated Nov 8, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.